Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Full text not currently available from Enlighten.
Abstract
Background: Aromatase inhibitors have been used empirically to treat a subset of patients with hormone receptor positive uterine leiomyosarcomas(LMS) and carcinosarcomas (UCS) mainly supported by retrospective data. We evaluated the activity of anastrozole in two rare cohorts; patients with recurrent/metastatic LMS and UCS enrolled in PARAGON, a basket trial of anastrozole in estrogen receptor (ER+)/progesterone receptor positive (PR+) gynecological cancers. Method: An investigator-initiated, single-arm, prospective open-label trial of anastrozole 1 mg/day in patients with ER & /or PR + ve LMS or UCS with measurable disease, treated until progression or unacceptable toxicity. Primary endpoint was clinical benefit (complete/partial response + stable disease) rate (CBR) at 3 months. Secondary endpoints include progression-free survival (PFS), quality of life and toxicity. Results: 39 eligible patients were enrolled, 32 with LMS and 7 with UCS. For the LMS cohort CBR at 3 months was 35% (95% CI: 21–53%) with a median duration of clinical benefit of 5.8 months. Best response was a partial response in one patient. Two patients remained on treatment for more than one year. The median progression-free survival was 2.8 months (95% CI: 2.6–4.9). For the UCS cohort CBR at 3 months was 43% (95% CI: 16–75%) with a median duration of clinical benefit of 5.6 months. Stable disease was seen in 3 patients but no objective responses were seen. The median progression-free survival was 2.7 months (95% CI, 1.1–8.2). Safety was acceptable with 5/39 evaluable patients showing grade 3 toxicities. Conclusion: Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS.
Item Type: | Articles |
---|---|
Additional Information: | This research was supported by a Cancer Australia Grant 632740 (2009–2011), Cancer Australia Priority-Driven Collaborative Research Scheme Project Grant 1063014 (2014–2016), Cancer Australia Priority-Driven Collaborative Cancer Research Scheme Project Grant 1142697, Cancer Research UK (C22375/A12846 and C22375/A13784), and Cancer Institute New South Wales Research Infrastructure Grant 15/RIG/1-16. UK Co-Sponsors: NHS Greater Glasgow and Clyde and University of Glasgow. Anastrozole was provided by AstraZeneca. |
Keywords: | Aromatase inhibitor, Uterine leiomyosarcoma, Uterine carcinosarcoma |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Alexander, Mrs Laura and Millan, Dr David and Kelly, Mrs Caroline and Carty, Mrs Karen and Divers, Miss Laura |
Authors: | Edmondson, R. J., O'Connell, R. L., Banerjee, S., Mileshkin, L., Sykes, P., Beale, P., Fisher, A., Bonaventura, A., Millan, D., Nottley, S., Benson, C., Hamilton, A., Sjoquist, K., Alexander, L., Kelly, C., Carty, K., Divers, L., Bradshaw, N., Friedlander, M., and on behalf of PARAGON investigators, |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Gynecologic Oncology |
Publisher: | Elsevier |
ISSN: | 0090-8258 |
ISSN (Online): | 1095-6859 |
Published Online: | 05 October 2021 |
University Staff: Request a correction | Enlighten Editors: Update this record